<DOC>
	<DOCNO>NCT00171912</DOCNO>
	<brief_summary>This trial various type malignancy may depend certain enzyme ( tyrosine kinase ) growth . The objective study assess extent imatinib mesylate block enzymes assess effect malignancy .</brief_summary>
	<brief_title>Imatinib Mesylate Patients With Various Types Malignancies Involving Activated Tyrosine Kinase Enzymes</brief_title>
	<detailed_description>Condition Diverse malignancy either associate thought associate activated tyrosine kinase enzymes include hypereosinophilic syndrome systemic mastocytosis chronic myelomonocytic leukaemia , dermatofibrosarcoma protuberans disease . Not include : Patients chronic myeloid leukemia , type leukemias ( abl-mutated ) type gastrointestinal stromal tumour ( c-KIT-positive ) , systemic mastocytosis ( c-KIT D816V mutation ) , brain , prostate , breast lung cancer .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Mastocytosis , Systemic</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Dermatofibrosarcoma</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Malignancy likely relate activated tyrosine kinase enzyme sensitive imatinib mesylate . 2 . Spread disease rest body ( confirmed tissue sample ) beyond skin . 3 . Malignant tissue show activation certain tyrosine kinase ( ABL , ARG , KIT ( CD117 ) , PDGFR alpha beta ) &amp; preferably within 6 week entry . 1 . Certain leukaemias ( ablmutated ) , gastrointestinal stromal tumour ( cKITpositive ) certain systemic mastocytosis ( c KIT D816V mutation ) . 2 . A primary prostate , breast , lung brain tumour , 3 . Patient previously treat imatinib mesylate except treatment 6 month previously suggestion clinical resistance lack response . Other protocoldefined inclusion / exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Imatinib mesylate</keyword>
	<keyword>tyrosine kinase</keyword>
	<keyword>imatinib sensitivity</keyword>
	<keyword>Diverse malignancy either associate</keyword>
	<keyword>thought associate</keyword>
	<keyword>activate tyrosine kinase enzyme</keyword>
	<keyword>include hypereosinophilic syndrome</keyword>
	<keyword>systemic mastocytosis</keyword>
	<keyword>chronic myelomonocytic leukaemia ,</keyword>
	<keyword>dermatofibrosarcoma protuberans disease .</keyword>
	<keyword>Not include :</keyword>
	<keyword>patient chronic myeloid leukemia ,</keyword>
	<keyword>type leukemia ( abl-mutated )</keyword>
	<keyword>type gastrointestinal stromal tumour ( c-KIT-positive ) ,</keyword>
	<keyword>systemic mastocytosis ( c-KIT D816V mutation ) ,</keyword>
	<keyword>brain ,</keyword>
	<keyword>prostate ,</keyword>
	<keyword>breast lung cancer .</keyword>
</DOC>